SAN DIEGO, May 30, 2013 /PRNewswire/ -- Sorrento
Therapeutics (OTCBB: SRNE; or STI) today announced that
Henry Ji, Ph.D., the Company's
President and Chief Executive Officer, will present at the
Jefferies 2013 Global Healthcare Conference on Thursday, June 6th, 2013, at
3:00 PM ET. The conference will be
held at the Grand Hyatt in New York,
NY.
A live webcast of the presentation will be available at the
start time of the presentation by accessing
http://wsw.com/webcast/jeff77/srne/. Following the live
presentation, a replay of the webcast will be available for 90
days.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc. is a publicly-traded,
development-stage biopharmaceutical company focused on the
acquisition, discovery, development and commercialization of novel
and proprietary biotherapeutics for the treatment of a variety of
disease conditions, including cancer, inflammation, metabolic and
infectious diseases. STI's objective is to identify drug
development candidates derived from its proprietary human antibody
libraries and, either independently or through partnerships,
advance selected targets into preclinical or clinical development.
In 2012, STI identified and further developed a number of potential
drug product candidates across various therapeutic areas. STI
intends to select several lead product candidates to progress into
preclinical development activities in 2013, including human
anti-PD-L1 and anti-PD-1 monoclonal antibodies (mAbs) that have
demonstrated strong immunomodulatory activity in vitro comparable
to competitor mAbs currently in clinical development as well as
significant anti-cancer activity in a tumor mouse model.
Forward-Looking Statements
This press release contains forward-looking statements subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. Words such as "plans,"
"believes," "expects," "anticipates," and "will," and similar
expressions, are intended to identify forward-looking statements.
Forward-looking statements include statements about the preclinical
and clinical development of STI's human antibody therapeutics. All
such forward-looking statements are based on STI's current beliefs
and expectations, and should not be regarded as a representation by
STI that any of its plans will be achieved. Actual results may
differ materially from those set forth in this press release due to
the risks and uncertainties inherent in STI's businesses; the scope
and validity of patent protection for STI's platform technologies,
and the risk that the development or commercialization of product
candidates may infringe the intellectual property rights of others;
the potential that STI may require substantial additional funding
in order to obtain regulatory approval for and commercialize quorum
quenching technologies or any other product; and additional risks
set forth in Sorrento Therapeutics' filings with the Securities and
Exchange Commission. These forward-looking statements represent
Sorrento Therapeutics' judgment as of the date of this release. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and STI undertakes no obligation to revise or
update this press release to reflect events or circumstances after
the date hereof. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation
Reform Act of 1995.
SOURCE Sorrento Therapeutics, Inc.